Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish

References

• Abbate E, Vescovo M, Natiello M, Cufre M, Garcia A, Gonzalez Montaner P, et al. 2012. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother 67:473–7
   PubMed Web of Science ®Google Scholar
• Adams KN, Szumowski JD, Ramakrishnan L. 2014. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J Infect Dis 210:456–66
   PubMed Web of Science ®Google Scholar
• Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, et al. 2011. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145:39–53
   PubMed Web of Science ®Google Scholar
• Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, Van Soolingen D. 2010. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 35:524–6
   PubMed Web of Science ®Google Scholar
• Amaral L, Kristiansen JE, Viveiros M, Atouguia J. 2001. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J Antimicrob Chemother 47:505–11
   PubMed Web of Science ®Google Scholar
• Amaral L, Molnar J. 2012. Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis. Expert Rev anti Infect Ther 10:869–73
   PubMed Web of Science ®Google Scholar
• Amaral L, Viveiros M. 2012. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents 39:376–80
   PubMed Web of Science ®Google Scholar
• Bettencourt MV, Bosne-David S, Amaral L. 2000. Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 16:69–71
   PubMed Web of Science ®Google Scholar
• Buckley NA, Whyte IM, Dawson AH. 1995. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 33:199–204
   PubMed Web of Science ®Google Scholar
• Couvreur P, Vauthier C. 2006. Nanotechnology: intelligent design to treat complex disease. Pharm Res 23:1417–50
   PubMed Web of Science ®Google Scholar
• D’amico LS, Seng Wl, Yang Y, Suter W. 2012. Assessment of drug-induced cardiotoxicity in zebrafish. In: McGrath P, ed. Zebrafish: Methods for Assessing Drug Safety and Toxicity. New Jersey: John Wiley & Sons, Inc, 45–54
   Google Scholar
• Da Silva PE, Von Groll A, Martin A, Palomino JC. 2011. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 63:1–9
   PubMed Web of Science ®Google Scholar
• De Knegt GJ, Ten Kate MT, Van Soolingen D, Aarnoutse R, Boeree MJ, Bakker-Woudenberg IJM, De Steenwinkel JEM. 2014. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. Tuberculosis 94:701–7
   PubMed Web of Science ®Google Scholar
• Dutta NK, Pinn ML, Zhao M, Rudek MA, Karakousis PC. 2013. Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis. J Antimicrob Chemother 68:1327–30
   PubMed Web of Science ®Google Scholar
• Fenaroli F, Westmoreland D, Benjaminsen J, Kolstad T, Skjeldal FM, Meijer AH, et al. 2014. Nanoparticles as drug delivery system against tuberculosis in zebrafish embryos: direct visualization and treatment. ACS Nano 8:7014–26
   PubMed Web of Science ®Google Scholar
• Gillespie SH. 2002. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 46:267–74
   PubMed Web of Science ®Google Scholar
• Griffiths G, Nystrom B, Sable SB, Khuller GK. 2010. Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol 8:827–34
   PubMed Web of Science ®Google Scholar
• Haldi MH, Delisle M, D’amico L, Delise A, Seng WL. 2012. Developmental toxicity assessment in zebrafish. In: McGrath P, ed. Zebrafish: Methods for Assessing Drug Safety and Toxicity. New Jersey: John Wiley & Sons, Inc, 15–25
   Google Scholar
• Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K. 1996. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19:1518–20
   PubMed Web of Science ®Google Scholar
• Kalluru R, Fenaroli F, Westmoreland D, Ulanova L, Maleki A, Roos N, et al. 2013. Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes. J Cell Sci 126:3043–54
   PubMed Web of Science ®Google Scholar
• Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. 2012. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 41:2971–3010
   PubMed Web of Science ®Google Scholar
• Kester JC, Fortune SM. 2014. Persisters and beyond: mechanisms of phenotypic drug resistance and drug tolerance in bacteria. Crit Rev Biochem Mol Biol 49:91–101
   PubMed Web of Science ®Google Scholar
• Martinez JL, Sanchez MB, Martinez-Solano L, Hernandez A, Garmendia L, Fajardo A, Alvarez-Ortega C. 2009. Functional role of bacterial multidrug efflux pumps in microbial natural ecosystems. FEMS Microbiol Rev 33:430–49
   PubMed Web of Science ®Google Scholar
• Mitchison D, Davies G. 2012. The chemotherapy of tuberculosis: past, present and future [State of the art]. Int J Tuberc Lung Dis 16:724–32
   PubMed Web of Science ®Google Scholar
• Niederweis M. 2003. Mycobacterial porins-new channel proteins in unique outer membranes. Mol Microbiol 49:1167–77
   PubMed Web of Science ®Google Scholar
• Ordway D, Viveiros M, Leandro C, Arroz MJ, Amaral L. 2002. Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus. Int J Antimicrob Agents 20:34–43
   PubMed Web of Science ®Google Scholar
• Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, et al. 2003. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 47:917–22
   PubMed Web of Science ®Google Scholar
• Palha N, Guivel-Benhassine F, Briolat V, Lutfalla G, Sourisseau M, Ellett F, et al. 2013. Real-time whole-body visualization of Chikungunya virus infection and host interferon response in zebrafish. PLoS Pathog 9:e1003619
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, Gumbo T. 2011. A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol 11:457–63
   PubMed Web of Science ®Google Scholar
• Poole K. 2007. Efflux pumps as antimicrobial resistance mechanisms. Ann Med 39:162–76
   PubMed Web of Science ®Google Scholar
• Putman M, Van Veen HW, Konings WN. 2000. Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev 64:672–93
   PubMed Web of Science ®Google Scholar
• Ramakrishnan L. 2012. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 12:352–66
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Musser JM. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 79:3–29
   PubMedGoogle Scholar
• Rodrigues L, Machado D, Couto I, Amaral L, Viveiros M. 2012. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol 12:695–700
   PubMed Web of Science ®Google Scholar
• Saotome K, Morita H, Umeda M. 1989. Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxicol In Vitro 3:317–21
   PubMed Web of Science ®Google Scholar
• Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. 2012. Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–82
   PubMed Web of Science ®Google Scholar
• Singh A, Sharma S. 2014. Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis. Tuberculosis 94:695–700
   PubMed Web of Science ®Google Scholar
• TB CARE I. 2014. International Standards for Tuberculosis Care. 3rd edn. The Hague: TB CARE I
   Google Scholar
• Thanacoody RH. 2011. Thioridazine: the good and the bad. Recent Pat Antiinfect Drug Discov 6:92–8
   PubMedGoogle Scholar
• Troegeler A, Lastrucci C, Duval C, Tanne A, Cougoule C, Maridonneau-Parini I, et al. 2014. An efficient siRNA-mediated gene silencing in primary human monocytes, dendritic cells and macrophages. Immunol Cell Biol 92:699–708
   PubMed Web of Science ®Google Scholar
• Tuomanen E. 1986. Phenotypic tolerance: the search for β-lactam antibiotics that kill nongrowing bacteria. Rev Infec Dis 8:S279–91
   PubMedGoogle Scholar
• Van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, et al. 2010. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 5:e12640
   PubMed Web of Science ®Google Scholar
• Viveiros M, Martins M, Rodrigues L, Machado D, Couto I, Ainsa J, Amaral L. 2012. Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Rev anti Infect Ther 10:983–98
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2014. Global Tuberculosis Report 2014, Geneva
   Google Scholar
• Zhu JJ, Xu YQ, He JH, Yu HP, Huang CJ, Gao JM, et al. 2014. Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish. J Appl Toxicol 34:139–48
   PubMed Web of Science ®Google Scholar